Celularity Inc. Increase (Decrease) in Derivative Liabilities
Celularity Inc. (CELU) reported Increase (Decrease) in Derivative Liabilities of -$34.45 million for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-19.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInDerivativeLiabilities · last filed 2021-08-19
- Celularity Inc. increase (decrease) in derivative liabilities for the quarter ending 2021-06-30 was $5.56M, a 53.56% decline year-over-year.
- Celularity Inc. increase (decrease) in derivative liabilities for the quarter ending 2021-03-31 was -$40.01M.
- Celularity Inc. increase (decrease) in derivative liabilities for the quarter ending 2020-06-30 was $11.97M.
- Celularity Inc. increase (decrease) in derivative liabilities for the quarter ending 2020-03-31 was -$5.34M.
| Period end | Increase (Decrease) in Derivative Liabilities 3 month | Increase (Decrease) in Derivative Liabilities 6 month |
|---|---|---|
| 2021-06-30 | $5.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-19 | -$34.45M 10-Q · filed 2021-08-19 |
| 2021-03-31 | -$40.01M 10-Q · filed 2021-05-24 | |
| 2020-06-30 | $11.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-19 | $6.62M 10-Q · filed 2021-08-19 |
| 2020-03-31 | -$5.34M 10-Q · filed 2021-05-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |